Merola E, Dal Buono A, Denecke T, Arsenic R, Pape UF, Jann H, Wiedenmann B, Pavel ME
Pancreas 2020 Aug;49(7):912-917. doi: 10.1097/MPA.0000000000001593. PMID: 32658073

Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.

Khetan P, Oyewole F, Wolin E, Kim MK, Divino CM
Pancreas 2020 Apr;49(4):509-513. doi: 10.1097/MPA.0000000000001520. PMID: 32224719

Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.

de Mestier L, Walter T, Brixi H, Evrard C, Legoux JL, de Boissieu P, Hentic O, Cros J, Hammel P, Tougeron D, Lombard-Bohas C, Rebours V, Ruszniewski P, Cadiot G
Neuroendocrinology 2019;108(4):343-353. Epub 2019 Feb 13 doi: 10.1159/000498887. PMID: 30759445

Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter Study.

Zhu LM, Tang L, Qiao XW, Wolin E, Nissen NN, Dhall D, Chen J, Shen L, Chi Y, Yuan YZ, Ben QW, Lv B, Zhou YR, Bai CM, Chen J, Song YL, Song TT, Lu CM, Yu R, Chen YJ
Medicine (Baltimore) 2016 Feb;95(7):e2836. doi: 10.1097/MD.0000000000002836. PMID: 26886644 Free PMC Article

See all (13)

Diagnosis

Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.

Parisi A, Delaunay B, Pinterpe G, Hollebecque A, Blanc JF, Bouattour M, Assenat E, Ben Abdelghani M, Sarabi M, Niger M, Vivaldi C, Mandalà M, Palloni A, Bensi M, Garattini SK, Tougeron D, Combe P, Salati M, Rimini M, Cella CA, Tucci M, Diana A, Mori E, Longarini R, Artru P, Roth G, Evesque L, Vienne A, Turpin A, Hiret S, Bourgeois V, Herve C, Paulon R, Stacoffe M, Malka D, Neuzillet C, Edeline J, Lievre A, Guimbaud R, Chapda MCP, Rimassa L, Giampieri R, Valle J, Berardi R, Fares N
Eur J Cancer 2024 Mar;200:113587. Epub 2024 Feb 6 doi: 10.1016/j.ejca.2024.113587. PMID: 38340384

Nationwide registry for patients with neuroendocrine neoplasm of pancreas, gastrointestinal tract, lungs, bronchi, or thymus in Japan.

Masui T, Ito T, Komoto I, Kojima S, Kasai Y, Tanabe M, Hara K, Hirano S, Okusaka T, Ichikawa Y, Kinugasa Y, Kokudo N, Kudo A, Sakurai A, Sugihara K, Date H, Haruma K, Hijioka S, Hirata K, Yamano H, Sakamine M, Kikuchi T, Fukushima M, Imamura M, Uemoto S
Int J Clin Oncol 2022 May;27(5):840-849. Epub 2022 Feb 18 doi: 10.1007/s10147-022-02130-y. PMID: 35178624 Free PMC Article

Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.

Khetan P, Oyewole F, Wolin E, Kim MK, Divino CM
Pancreas 2020 Apr;49(4):509-513. doi: 10.1097/MPA.0000000000001520. PMID: 32224719

Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors.

Milione M, Maisonneuve P, Pellegrinelli A, Pusceddu S, Centonze G, Dominoni F, Brambilla C, Rubino M, Faggiano A, Buzzoni R, Concas L, Giacomelli L, Coppa J, Mazzaferro V, de Braud F
Endocrine 2017 Sep;57(3):512-517. Epub 2016 Nov 30 doi: 10.1007/s12020-016-1180-6. PMID: 27905048

Prognostic impact of diagnosing colorectal neuroendocrine carcinoma using the World Health Organization 2010 classification.

Lee JL, Yu CS, Kim M, Hong SM, Lim SB, Kim JC
Surgery 2014 Apr;155(4):650-8. Epub 2013 Nov 22 doi: 10.1016/j.surg.2013.11.012. PMID: 24468036

See all (5)

Therapy

Safety and efficacy of the FLOT regimen in the Polish population - an analysis of the prospective trial.

Marcisz-Grzanka K, Winiarek M, Pałucki J, Wieszczy P, Olesiński T, Jóźwiak M, Samsel R, Sułkowska U, Kolasińska-Ćwikła A, Wyrwicz LS
Neoplasma 2022 Dec;69(6):1445-1450. Epub 2022 Nov 11 doi: 10.4149/neo_2022_220720N734. PMID: 36353936

Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms.

Merola E, Dal Buono A, Denecke T, Arsenic R, Pape UF, Jann H, Wiedenmann B, Pavel ME
Pancreas 2020 Aug;49(7):912-917. doi: 10.1097/MPA.0000000000001593. PMID: 32658073

Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.

Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Hasegawa S, Kobayashi N, Tokuhisa M, Goto A, Takano S, Takada Y, Kaneta T, Mori R, Matsuyama R, Endo I, Yamanaka S, Nakajima A, Inoue T, Ichikawa Y
Digestion 2017;96(1):13-20. Epub 2017 Jun 14 doi: 10.1159/000470838. PMID: 28609761

Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.

Fazio N, Milione M
Cancer Treat Rev 2016 Nov;50:61-67. Epub 2016 Aug 28 doi: 10.1016/j.ctrv.2016.08.006. PMID: 27636009

See all (5)

Prognosis

Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.

Xu JX, Wu DH, Ying LW, Hu HG
World J Gastroenterol 2021 Dec 21;27(47):8123-8137. doi: 10.3748/wjg.v27.i47.8123. PMID: 35068858 Free PMC Article

Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms.

Merola E, Dal Buono A, Denecke T, Arsenic R, Pape UF, Jann H, Wiedenmann B, Pavel ME
Pancreas 2020 Aug;49(7):912-917. doi: 10.1097/MPA.0000000000001593. PMID: 32658073

Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.

Khetan P, Oyewole F, Wolin E, Kim MK, Divino CM
Pancreas 2020 Apr;49(4):509-513. doi: 10.1097/MPA.0000000000001520. PMID: 32224719

Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.

Fazio N, Milione M
Cancer Treat Rev 2016 Nov;50:61-67. Epub 2016 Aug 28 doi: 10.1016/j.ctrv.2016.08.006. PMID: 27636009

Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter Study.

See all (12)

Clinical prediction guides

Endoscopic mucosal resection: still a reliable therapeutic option for gastrointestinal neuroendocrine tumors.

Sivandzadeh GR, Ejtehadi F, Shoaee S, Aminlari L, Niknam R, Taghavi AR, Geramizadeh B, Hormati A, Safarpour AR, Bagheri Lankarani K
BMC Gastroenterol 2021 May 24;21(1):238. doi: 10.1186/s12876-021-01821-6. PMID: 34030644 Free PMC Article

Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.

Khetan P, Oyewole F, Wolin E, Kim MK, Divino CM
Pancreas 2020 Apr;49(4):509-513. doi: 10.1097/MPA.0000000000001520. PMID: 32224719

Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.

Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors.

Han X, Zhao J, Ji Y, Xu X, Lou W
Tumour Biol 2013 Oct;34(5):2881-9. Epub 2013 May 19 doi: 10.1007/s13277-013-0850-8. PMID: 23686805

See all (6)